Now showing items 1-2 of 2

    • Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis 

      Berry, James Dale; Shefner, Jeremy M.; Conwit, Robin; Schoenfeld, David Alan; Keroack, Myles; Felsenstein, Donna; Krivickas, Lisa; David, William Samuel; Vriesendorp, Francine; Pestronk, Alan; Caress, James B.; Katz, Jonathan; Simpson, Ericka; Rosenfeld, Jeffrey; Pascuzzi, Robert; Glass, Jonathan; Rezania, Kourosh; Rothstein, Jeffrey D.; Greenblatt, David J.; Cudkowicz, Merit Ester (Public Library of Science, 2013)
      Objectives: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases ...
    • FUS is sequestered in nuclear aggregates in ALS patient fibroblasts 

      Schwartz, Jacob C.; Podell, Elaine R.; Han, Steve S. W.; Berry, James D.; Eggan, Kevin C.; Cech, Thomas R. (The American Society for Cell Biology, 2014)
      Mutations in the RNA-binding protein FUS have been shown to cause the neurodegenerative disease amyotrophic lateral sclerosis (ALS). We investigate whether mutant FUS protein in ALS patient–derived fibroblasts affects ...